Status:
RECRUITING
A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma
Lead Sponsor:
University of Aarhus
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hepatocellular carcinoma (HCC) is the most common primary liver tumour and is the fourth leading cause of cancer-related death worldwide. In Denmark, the incidence of HCC is 5.2 per 100.000 population...
Eligibility Criteria
Inclusion
- patients with hepatocellular carcinoma
- age above 18 years
Exclusion
- the patient does not want to take part in the study
- the responsible investigator determines that the patient is not qualified for a PET scan
- a history of moderate or intense hypersensitivity to a gadolinium-based contrast agent
- renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73 m2 body surface area
- contraindications for MRI including claustrophobia
- pregnant or nursing patients.
Key Trial Info
Start Date :
January 16 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05359939
Start Date
January 16 2023
End Date
December 1 2025
Last Update
December 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8200